Latest News

Latest News

From GLP-1 Trial Results to the Follow-Up Visit

From GLP-1 Trial Results to the Follow-Up Visit

A patient returns for follow-up after starting a GLP-1 receptor agonist. Their weight is down, but nausea has made meals unpredictable, and their insurer has declined the next refill. The GLP-1 trial results that helped start the conversation are still relevant. The...

read more

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Eppendorf and BioLabs Expand Collaboration to Munich

Eppendorf and BioLabs Expand Collaboration to Munich

The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...

read more
ZW209 Licensing Deal: What Does Roche Get From Zymeworks?

ZW209 Licensing Deal: What Does Roche Get From Zymeworks?

Under the ZW209 licensing deal with Zymeworks, Roche will receive exclusive global rights to develop and commercialise ZW209. In return, Zymeworks is due $55 million upfront and $40 million when a Phase 1b trial begins. It is also eligible for up to $718 million in...

read more
OOS Investigation: A Solubility-Related HPLC Assay Failure

OOS Investigation: A Solubility-Related HPLC Assay Failure

A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...

read more
Connecting ADME and Mouse Models in Preclinical Oncology

Connecting ADME and Mouse Models in Preclinical Oncology

In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...

read more
Eppendorf and BioLabs Expand Collaboration to Munich

Eppendorf and BioLabs Expand Collaboration to Munich

The collaboration will provide laboratory equipment, technical support and engagement opportunities for BioLabs resident companies. It builds on existing partnerships at BioLabs sites across the US, Germany and France. HAMBURG and MUNICH, Germany, 21 October 2026...

read more
ZW209 Licensing Deal: What Does Roche Get From Zymeworks?

ZW209 Licensing Deal: What Does Roche Get From Zymeworks?

Under the ZW209 licensing deal with Zymeworks, Roche will receive exclusive global rights to develop and commercialise ZW209. In return, Zymeworks is due $55 million upfront and $40 million when a Phase 1b trial begins. It is also eligible for up to $718 million in...

read more
OOS Investigation: A Solubility-Related HPLC Assay Failure

OOS Investigation: A Solubility-Related HPLC Assay Failure

A low out-of-specification (OOS) assay result does not always originate in the analytical laboratory. In pharmaceutical manufacturing, an OOS investigation must consider laboratory testing, raw material properties, manufacturing instructions and process execution...

read more
Connecting ADME and Mouse Models in Preclinical Oncology

Connecting ADME and Mouse Models in Preclinical Oncology

In preclinical oncology, a tumor study can show little benefit even when a candidate has strong activity in cultured cells. Before abandoning the compound, researchers need to establish what the result means. Did enough drug reach the tumor? Was the proposed target...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Weekly News Roundup | 26 October 2026

Weekly News Roundup | 26 October 2026

Life science news 26 October 2026: two major deals, three US approvals, two UK updates and a reverse merger. Roche signed an antibody-drug conjugate deal with Hansoh. Merck KGaA agreed to buy Silence Therapeutics for about $1.3bn. The FDA granted accelerated approval...

read more
Clinical Trial Results 23 October 2026

Clinical Trial Results 23 October 2026

The clinical trial results 23 October 2026 cover non-infectious uveitis, hidradenitis suppurativa, IgA nephropathy, wet AMD and metastatic colorectal cancer. Priovant’s brepocitinib met its primary endpoint in two Phase 3 trials in non-infectious uveitis. AbbVie’s...

read more

Further News

Preservative-Free Is Not Risk-Free: The Microbiology Behind Safe Cosmetics

I have noticed that many shoppers want cosmetics without preservatives, so brands have launched preservative-free cosmetics and other “free-from” lines. The science of microbiology however stays the same. Any product that holds water and nutrients can feed microbes....

COMP360 Approval: When Could Compass’s Psilocybin Be Cleared?

No COMP360 approval date exists yet, but the timetable is short. Compass Pathways said its rolling new drug application (NDA) should finish “in the next two weeks”. It made the statement on 3 November 2026, in its third-quarter 2026 results release. The company...

What Happens After a Digital Mental Health Screening Result

A self-assessment can identify symptoms, but the value of mental health screening depends on what people understand, choose and can access after seeing the result. A person completes an online mental health questionnaire and receives a score suggesting that...

Rethinking Biologics Plants to Earn Attractive Returns

The rapid growth of biologics and other advanced therapeutic modalities is transforming pharmaceutical R&D and manufacturing. From monoclonal antibodies and oligonucleotides to cell and gene therapies, these products introduce a level of process complexity,...

BioMarin Fabry Deal: What Does It Get for $70 Million Upfront?

The BioMarin Fabry deal gives the US company exclusive worldwide rights, outside Korea, to an early-stage injectable enzyme therapy. BioMarin announced the licence on 29 October 2026 with GC Biopharma and Hanmi Pharm. The candidate is HM15421/GC1134A, also known as...

The Fifty-Year Chase: Where Noninvasive Glucose Monitoring Stands in 2026

For nearly half a century, one problem has raised more capital, had more publications, and experienced more failed product launches than almost any other in medical devices: noninvasive glucose monitoring, or measuring blood glucose without breaking the skin. More...

ObesityWeek 2026 Preview: The Data to Watch in Washington

ObesityWeek 2026 runs from 14 to 17 November in National Harbor, Maryland, just outside Washington. The meeting is The Obesity Society’s 44th annual gathering. Novo Nordisk arrives with 26 abstracts, including the first results from REDEFINE 9, its lower-dose...

Extracellular Vesicles in Neurology: Is Translation Outpacing Science?

Extracellular vesicles are attracting growing attention in neurology because they can carry proteins, lipids and nucleic acids between cells and may reflect aspects of the biological state of their cells of origin. Their potential applications include liquid-biopsy...

BBP-418 Approval: When Could BridgeBio’s First LGMD Drug Launch?

BBP-418 approval is due by 27 November 2026. What the FDA is weighing for BridgeBio’s LGMD2I/R9 drug, and what the FORTIFY data show.

    When AI Writes Medical Device Requirements, What Does It Miss?

    Artificial intelligence is making its way into nearly every stage of medical device development, including one of the most foundational activities: defining product requirements. With a well-structured prompt, AI-generated requirements, spanning user needs, software...

    ULP Launches Founders’ Bench Award for Ophthalmology Innovation

    University Lab Partners Launches Inaugural Founders’ Bench Award to Accelerate Ophthalmology Innovation Bausch + Lomb joins as founding corporate partner; UCI’s Gavin Herbert Eye Institute serves as academic partner University Lab Partners (ULP) today announced the...

    The Weakest Link in Your Manuscript May Be the Image You Overlooked

    Image duplication, one of the most common image integrity problems in published research, can result from an inadvertent mix-up during figure preparation, reuse that has not been clearly explained, or deliberate fabrication. A 2025 analysis of the Retraction Watch...

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    See More Articles

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.